Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Imaging Tracer Agent (PSMA-Targeting C’ Dots) for the Detection of Prostate Cancer

Trial Status: active

This phase I trial studies how well an imaging tracer agent (PSMA-targeting C’ dots) works for the detection of prostate cancer. PSMA-targeting C’ dots is an imaging tracer agent targeted to the protein PSMA (prostate-specific membrane antigen), which is located only on prostate cancer cells. PET/MRI scans done after an injection of PSMA-targeting C’ dots may detect PSMA proteins more precisely than other imaging test. PSMA-targeting C’ dots tracer may help surgeons locate prostate cancer cells more accurately before and during surgery and improve diagnosis and treatment of prostate cancer.